Anyone researching cerebrolysin will find it discussed in the context of neurological conditions, but it is important to understand where it actually stands in clinical development. It does not currently carry an approved drug label.
Regulatory status
Cerebrolysin is an unapproved research compound. There is no approved prescribing label, so no FDA-recognized indications, mechanism of action, or dosing information can be cited here.
Trial footprint
There are 43 registered clinical trials involving cerebrolysin. Sampled studies illustrate the range of conditions under investigation, including a trial comparing it with prednisolone for Bell's palsy that is currently recruiting (phase 1/2), a study of neuroprotectants in acute ischemic stroke with an unknown status, and a trial examining its use after reperfusion in extended-window endovascular thrombectomy that has not yet begun recruiting. These listings reflect registered study activity, not evidence of safety or effectiveness.
FAQ
No. Cerebrolysin does not have an approved FDA label, and it is classified as an investigational research compound. No approved indications or dosing guidance exist for it.
Registered trials include research into Bell's palsy, acute ischemic stroke, and recovery after endovascular thrombectomy. These are active or planned studies, not proof that cerebrolysin works for these conditions.
There are 43 registered clinical trials listed for cerebrolysin as of the latest data pull. This count includes trials in various phases and statuses, from recruiting to not yet recruiting.
No adverse event report data is available for cerebrolysin in the data reviewed here. This does not mean side effects do not exist, only that no such information was provided in this dataset.
A recruiting trial is actively enrolling participants, while a not-yet-recruiting trial has been registered but has not started enrollment. Both statuses indicate research is ongoing or planned, not completed.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: ClinicalTrials.gov
Updated 2026-11-07